Thermo Fisher (TMO) At A 52-Week High: What's Driving It?
Zacks Investment Research | Dec 08, 2019 09:18PM ET
On Dec 6, shares of Thermo Fisher (NYSE:TMO) scaled a new 52-week high of $321.60, closing the session marginally lower at $320.12. In fact, the stock has rallied nearly 7.8% since its third-quarter earnings announcement on Oct 23.
Strength in majority of end markets, solid international performance and impressive full-year guidance prompted the rally.
Let us take a closer look at the factors driving growth.
Robust Q3 Earnings
The company exited the third quarter on a promising note, with better-than-expected earnings and revenue numbers.Revenues for the quarter improved 12.2% year over year, driven by robust performances by Life Sciences Solutions, Analytical Instruments and Laboratory Products and Services segments.
Adjusted operating margin for the quarter was 22.5%, reflecting an expansion of 27 basis points (bps).
The lifted revenue and adjusted EPS outlook for 2019 buoys optimism among investors, indicating the continuation of this bullish trend through the rest of the year.
Other Encouraging Factors
In October 2019, Thermo Fisher completed the acquisition of an active pharmaceutical ingredient manufacturing facility from GlaxoSmithKline for €90 million.The company also started benefiting from the synergy of the recently-acquired HighChem, a small business that broadens the former’s mass spectrometry software portfolio.
Moreover, investors are optimistic about the company continuing to strengthen its foothold in several emerging markets. In the third quarter of 2019, China has been the biggest contributor, with the company registering 30% growth rate in the country.
In September, the company launched the next-generation Thermo Scientific DXR3 Family of Raman Spectrometers and Microscopes. Around the same time, it entered into an agreement with Eli Lilly and Company (NYSE:LLY) for the development of a companion diagnostic that will utilize the FDA-cleared, next-generation sequencing-based Oncomine Dx Target (NYSE:TGT) Test to identify certain non-small cell lung cancer and thyroid cancer patients who may be treated with Lilly's investigational therapy, LOXO-292.
Meanwhile, Thermo Fisher has been having a great run on the bourses in the past year. The stock has rallied 35%, higher than the broader Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.